Observational analysis measures vaccine effectiveness in US adults, suggesting notable protection duration.
Vaccine effectiveness (VE) of BNT162b2 KP.2 vaccine against COVID-19 hospital admissions was 49% [95%CI:30–63]) and 45% (95%CI:35–54) against ED/UC encounters (versus no KP.2 vaccine at <3 months). Protection persisted >90 days from vaccination with some waning. VE remained high regardless of prior COVID-19 vaccination and among older adults.
No takes yet. Share an insight, caveat, or question.
Tartof et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: